| Ident. | Authors (with country if any) | Title |
|---|
| 000052 (2021) |
Santanu Santra [Inde] ; Santanab Giri [Inde] ; Madhurima Jana [Inde] | Unraveling the origin of interactions of hydroxychloroquine with the receptor-binding domain of SARS-CoV-2 in aqueous medium. |
| 000127 (2021) |
Thirumal Kumar D [Inde] ; Nishaat Shaikh [Inde] ; Udhaya Kumar S [Inde] ; George Priya Doss C [Inde] ; Hatem Zayed [Qatar] | Structure-Based Virtual Screening to Identify Novel Potential Compound as an Alternative to Remdesivir to Overcome the RdRp Protein Mutations in SARS-CoV-2. |
| 000169 (2021) |
Bianca D. Balmant [Brésil] ; Raquel S. Torrinhas [Brésil] ; Ilanna M. Rocha [Brésil] ; Danielle C. Fonseca [Brésil] ; Francisco F C. Formiga [Brésil] ; Eloisa S D O. Bonfá [Brésil] ; Eduardo F. Borba [Brésil] ; Dan L. Waitzberg [Brésil] | SARS-CoV-2 infection, gut dysbiosis, and heterogeneous clinical results of hydroxychloroquine on COVID-19 therapy-Is there a link? |
| 000183 (2021) |
Byung Jin Choi [Corée du Sud] ; Yeryung Koo [Corée du Sud] ; Tae Young Kim [Corée du Sud] ; Wou Young Chung [Corée du Sud] ; Yun Jung Jung [Corée du Sud] ; Ji Eun Park [Corée du Sud] ; Hong-Seok Lim [Corée du Sud] ; Bumhee Park [Corée du Sud] ; Dukyong Yoon [Corée du Sud] | Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice. |
| 000227 (2021) |
Iwein Gyselinck [Belgique] ; Wim Janssens [Belgique] ; Peter Verhamme [Belgique] ; Robin Vos [Belgique] | Rationale for azithromycin in COVID-19: an overview of existing evidence. |
| 000233 (2021) |
Olfa Noureddine [Tunisie] ; Noureddine Issaoui [Tunisie] ; Mouna Medimagh [Tunisie] ; Omar Al-Dossary [Arabie saoudite] ; Houda Marouani [Tunisie] | Quantum chemical studies on molecular structure, AIM, ELF, RDG and antiviral activities of hybrid hydroxychloroquine in the treatment of COVID-19: Molecular docking and DFT calculations. |
| 000265 (2021) |
Gayathri Baburaj [Inde] ; Levin Thomas [Inde] ; Mahadev Rao [Inde] | Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies. |
| 000279 (2021) |
Osama A. Badary [Égypte] | Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs. |
| 000295 (2021) |
Zheng Zequn [République populaire de Chine] ; Wu Yujia [République populaire de Chine] ; Qian Dingding [République populaire de Chine] ; Lian Jiangfang [République populaire de Chine] | Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel. |
| 000306 (2021) |
Pobitra Borah [Inde] ; Pran Kishore Deb [Jordanie] ; Balakumar Chandrasekaran [Jordanie] ; Manoj Goyal [Arabie saoudite] ; Monika Bansal [Arabie saoudite] ; Snawar Hussain [Arabie saoudite] ; Pottathil Shinu [Arabie saoudite] ; Katharigatta N. Venugopala [Afrique du Sud] ; Nizar A. Al-Shar'I [Jordanie] ; Satyendra Deka [Inde] ; Vinayak Singh [Afrique du Sud] | Neurological Consequences of SARS-CoV-2 Infection and Concurrence of Treatment-Induced Neuropsychiatric Adverse Events in COVID-19 Patients: Navigating the Uncharted. |
| 000307 (2021) |
Shweta A. More [Inde] ; Akshay S. Patil [États-Unis] ; Nikhil S. Sakle [Inde] ; Santosh N. Mokale [Inde] | Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs. |
| 000326 (2021) |
C N Prashantha [Inde] ; K. Gouthami [Inde] ; L. Lavanya [Inde] ; Sivaramireddy Bhavanam [Inde] ; Ajay Jakhar [Inde] ; R G Shakthiraju [Inde] ; V. Suraj [Inde] ; K V Sahana [Inde] ; H S Sujana [Inde] ; N M Guruprasad [Inde] ; R. Ramachandra [Inde] | Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus. |
| 000332 (2021) |
R K Hussein [Arabie saoudite] ; H M Elkhair [Arabie saoudite, Soudan] | Molecular docking identification for the efficacy of some zinc complexes with chloroquine and hydroxychloroquine against main protease of COVID-19. |
| 000345 (2021) |
Claudia Musial [Pologne] ; Magdalena Gorska-Ponikowska [Pologne] | Medical progress: Stem cells as a new therapeutic strategy for COVID-19. |
| 000370 (2021) |
Ágnes Telbisz [Hongrie] ; Csilla Ambrus [Hongrie] ; Orsolya M Zner [Hongrie] ; Edit Szab [Hongrie] ; György Várady [Hongrie] ; Éva Bakos [Hongrie] ; Balázs Sarkadi [Hongrie] ; Csilla Özvegy-Laczka [Hongrie] | Interactions of Potential Anti-COVID-19 Compounds with Multispecific ABC and OATP Drug Transporters. |
| 000396 (2021) |
Agata Blasiak ; Jhin Jieh Lim ; Shirley Gek Kheng Seah ; Theodore Kee ; Alexandria Remus ; De Hoe Chye ; Pui San Wong ; Lissa Hooi ; Anh T L. Truong ; Nguyen Le ; Conrad E Z. Chan ; Rishi Desai ; Xianting Ding ; Brendon J. Hanson ; Edward Kai-Hua Chow ; Dean Ho | IDentif.AI: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) with digital drug development. |
| 000445 (2021) |
Heba Hussein ; Ronald Brown [États-Unis] | Hydroxychloroquine and the treatment of Sjogren syndrome, chronic ulcerative stomatitis, and oral lichen planus in the age of COVID-19. |
| 000466 (2021) |
Iram Iqbal Hejazi [Inde] ; Md Amjad Beg [Inde] ; Md Ali Imam [Inde] ; Fareeda Athar [Inde] ; Asimul Islam [Inde] | Glossary of phytoconstituents: Can these be repurposed against SARS CoV-2? A quick in silico screening of various phytoconstituents from plant Glycyrrhiza glabra with SARS CoV-2 main protease. |
| 000510 (2021) |
Smarajit Maiti [Inde] ; Amrita Banerjee [Inde] | Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study. |
| 000515 (2021) |
Christian Skalafouris [Suisse] ; Caroline Samer [Suisse] ; Jerome Stirnemann [Suisse] ; Olivier Grosgurin [Suisse] ; François Eggimann [Suisse] ; Damien Grauser [Suisse] ; Jean-Luc Reny [Suisse] ; Pascal Bonnabry [Suisse] ; Bertrand Guignard [Suisse] | Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19. |
| 000552 (2021) |
Sook Wah Yee [États-Unis] ; Bianca Vora [États-Unis] ; Tomiko Oskotsky [États-Unis] ; Ling Zou [États-Unis] ; Sebastian Jakobsen [États-Unis] ; Osatohanmwen J. Enogieru [États-Unis] ; Megan L. Koleske [États-Unis] ; Idit Kosti [États-Unis] ; Mattias Rödin [États-Unis] ; Marina Sirota [États-Unis] ; Kathleen M. Giacomini [États-Unis] | Drugs in COVID-19 Clinical Trials: Predicting Transporter-Mediated Drug-Drug Interactions Using In Vitro Assays and Real-World Data. |
